Stifel Nicolaus Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)

Equities research analysts at Stifel Nicolaus assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm set a “buy” rating and a $86.00 price target on the stock. Stifel Nicolaus’ target price indicates a potential upside of 278.85% from the stock’s previous close.

Several other equities analysts have also issued reports on JSPR. Oppenheimer restated an “outperform” rating and set a $80.00 price target on shares of Jasper Therapeutics in a research note on Thursday, March 7th. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research note on Wednesday, May 15th. TD Cowen began coverage on Jasper Therapeutics in a research note on Monday, March 18th. They set an “outperform” rating on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research note on Tuesday, June 18th. Finally, Evercore ISI began coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an “outperform” rating and a $65.00 price objective on the stock. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $67.00.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $22.70 on Thursday. The business’s 50-day simple moving average is $23.12 and its 200-day simple moving average is $19.33. The firm has a market capitalization of $341.95 million, a PE ratio of -4.03 and a beta of 2.24. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.23. Research analysts forecast that Jasper Therapeutics will post -4.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of JSPR. Opaleye Management Inc. acquired a new position in shares of Jasper Therapeutics in the 4th quarter worth approximately $3,144,000. Kingdon Capital Management L.L.C. lifted its holdings in Jasper Therapeutics by 16.4% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after buying an additional 500,000 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Jasper Therapeutics during the 4th quarter worth $197,000. StemPoint Capital LP acquired a new position in Jasper Therapeutics during the 1st quarter worth $3,794,000. Finally, Ikarian Capital LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at $3,088,000. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.